MedTrace Logo

Immunological Profile of Solid Tumors Sample

NCT03311100 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1040

Last updated 2018-01-30

No results posted yet for this study

Summary

It has become clear in the recent year that the nature of the immune cells infiltrate within a tumor was essential in the control of the tumor growth. This so-called immune contexture does vary between cancer types and in response to treatments. In this context, this trial is a non-interventional, mono-centric in patients with solid tumors. Samples in paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or metastases) will be analysed. For each sample, clinically relevant data associated with treated cancer and needed for characterization of tumor microenvironment will be documented.

This trial is, through accessing to well documented selected archival tumor materials, to validate selected biomarker for early phase trial.

Conditions

  • Solid Cancer

Interventions

OTHER

immunohistochemistry assay

biomarkers expression

Sponsors & Collaborators

  • Innate Pharma

    collaborator INDUSTRY

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • ARNAUD Jean-Olivier, Director · Assistance Publique Hôpitaux de Marseille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-06
Primary Completion
2019-04-06
Completion
2020-04-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03311100 on ClinicalTrials.gov